Literature DB >> 26270355

Host stromal versican is essential for cancer-associated fibroblast function to inhibit cancer growth.

Kanda Fanhchaksai1,2, Futoshi Okada3, Naoko Nagai1, Peraphan Pothacharoen2, Prachya Kongtawelert2, Sonoko Hatano1, Shinji Makino4, Tomoyuki Nakamura5, Hideto Watanabe1.   

Abstract

The stroma provides a microenvironment that regulates tumor cell behavior. The extracellular matrix (ECM) has long been recognized to be important in tumor cell behavior, and previous studies have revealed the impact of individual matrix molecules on tumor progression. Although several reports have highlighted some central roles of tumor cell-expressed versican, the role of host stromal versican is not yet understood. In this study, we demonstrate that versican is an important molecule in the functional ECM structure and maintaining cancer-associated fibroblasts, using versican-negative QRsP11 fibrosarcoma cells. By their subcutaneous injection with cre-expressing adenoviruses to versican-floxed mice, we demonstrate that loss of host stromal versican facilitates tumor cell proliferation, and following angiogenesis, decreases cancer-associated fibroblasts, diminishes collagen fibers and alters hyaluronan distribution, concomitant with upregulation of hyaluronan, TGFβ and VEGF-mediated signaling. When the versican V3 variant consisting of G1 and G3 domains was expressed in tumor cells, it was integrated into the ECM, regained collagen fibers and cancer-associated fibroblasts and resulted in successful recovery of tumor growth inhibition, indicating that whatever cells produce, the G1 and G3 domains are adequate for versican function. Collectively, our results indicate a dynamic function of versican in the ECM that regulates tumor cell behavior. A greater understanding of the regulation of versican expression may contribute to the development of cancer therapies.
© 2015 UICC.

Entities:  

Keywords:  angiogenesis; cancer-associated fibroblast; microenvironment; proteoglycan; versican

Mesh:

Substances:

Year:  2015        PMID: 26270355     DOI: 10.1002/ijc.29804

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Authors:  Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

2.  Versican Deficiency Significantly Reduces Lung Inflammatory Response Induced by Polyinosine-Polycytidylic Acid Stimulation.

Authors:  Inkyung Kang; Ingrid A Harten; Mary Y Chang; Kathleen R Braun; Alyssa Sheih; Mary P Nivison; Pamela Y Johnson; Gail Workman; Gernot Kaber; Stephen P Evanko; Christina K Chan; Mervyn J Merrilees; Steven F Ziegler; Michael G Kinsella; Charles W Frevert; Thomas N Wight
Journal:  J Biol Chem       Date:  2016-11-28       Impact factor: 5.157

Review 3.  Versican and Versican-matrikines in Cancer Progression, Inflammation, and Immunity.

Authors:  Athanasios Papadas; Garrett Arauz; Alexander Cicala; Joshua Wiesner; Fotis Asimakopoulos
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

Review 4.  Versican: A Dynamic Regulator of the Extracellular Matrix.

Authors:  Shamima Islam; Hideto Watanabe
Journal:  J Histochem Cytochem       Date:  2020-09-10       Impact factor: 2.479

5.  Identification of novel ADAMTS1, ADAMTS4 and ADAMTS5 cleavage sites in versican using a label-free quantitative proteomics approach.

Authors:  Daniel R Martin; Salvatore Santamaria; Christopher D Koch; Josefin Ahnström; Suneel S Apte
Journal:  J Proteomics       Date:  2021-08-25       Impact factor: 4.044

6.  Comprehensive Analysis of VCAN Expression Profiles and Prognostic Values in HCC.

Authors:  Guangshun Sun; Wubin Zheng; Pengyu Tan; Jin Zhou; Weiwei Tang; Hongyong Cao; Li Liu; Xuesong Shi; Zhouxiao Li; Wenling Zhang
Journal:  Front Genet       Date:  2022-06-24       Impact factor: 4.772

7.  VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.

Authors:  Guangyan Zhangyuan; Fei Wang; Haitian Zhang; Runqiu Jiang; Xuewen Tao; Decai Yu; Kangpeng Jin; WeiWei Yu; Yang Liu; Yin Yin; Jintao Shen; Qinfeng Xu; Wenjie Zhang; Beicheng Sun
Journal:  Oncogene       Date:  2019-10-11       Impact factor: 9.867

8.  Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis.

Authors:  Keiichi Asano; Courtney M Nelson; Sumeda Nandadasa; Noriko Aramaki-Hattori; Daniel J Lindner; Tyler Alban; Junko Inagaki; Takashi Ohtsuki; Toshitaka Oohashi; Suneel S Apte; Satoshi Hirohata
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

9.  The synthesis and secretion of versican isoform V3 by mammalian cells: A role for N-linked glycosylation.

Authors:  Ingrid A Harten; Gernot Kaber; Kiran J Agarwal; Inkyung Kang; Sean Reyes Ibarrientos; Gail Workman; Christina K Chan; Mary P Nivison; Nadine Nagy; Kathleen R Braun; Michael G Kinsella; Mervyn J Merrilees; Thomas N Wight
Journal:  Matrix Biol       Date:  2020-01-27       Impact factor: 11.583

10.  ADAMTS1 protease is required for a balanced immune cell repertoire and tumour inflammatory response.

Authors:  Francisco Javier Rodríguez-Baena; Silvia Redondo-García; Carlos Peris-Torres; Estefanía Martino-Echarri; Rubén Fernández-Rodríguez; María Del Carmen Plaza-Calonge; Per Anderson; Juan Carlos Rodríguez-Manzaneque
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.